JP2023522198A5 - - Google Patents
Info
- Publication number
- JP2023522198A5 JP2023522198A5 JP2022562788A JP2022562788A JP2023522198A5 JP 2023522198 A5 JP2023522198 A5 JP 2023522198A5 JP 2022562788 A JP2022562788 A JP 2022562788A JP 2022562788 A JP2022562788 A JP 2022562788A JP 2023522198 A5 JP2023522198 A5 JP 2023522198A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fusion protein
- antigenic polypeptides
- immunogenic
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026008257A JP2026086469A (ja) | 2020-04-17 | 2026-01-21 | 黒色腫を治療するためのctl抗原の融合タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20170174 | 2020-04-17 | ||
| EP20170174.5 | 2020-04-17 | ||
| PCT/US2021/028029 WO2021212123A1 (en) | 2020-04-17 | 2021-04-19 | Fusion proteins of ctl antigens for treating melanoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026008257A Division JP2026086469A (ja) | 2020-04-17 | 2026-01-21 | 黒色腫を治療するためのctl抗原の融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023522198A JP2023522198A (ja) | 2023-05-29 |
| JP2023522198A5 true JP2023522198A5 (cg-RX-API-DMAC7.html) | 2024-05-20 |
Family
ID=70295067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562788A Pending JP2023522198A (ja) | 2020-04-17 | 2021-04-19 | 黒色腫を治療するためのctl抗原の融合タンパク質 |
| JP2026008257A Pending JP2026086469A (ja) | 2020-04-17 | 2026-01-21 | 黒色腫を治療するためのctl抗原の融合タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026008257A Pending JP2026086469A (ja) | 2020-04-17 | 2026-01-21 | 黒色腫を治療するためのctl抗原の融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230167163A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4136097A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023522198A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116057067A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3179694A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021212123A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3994156A1 (en) | 2019-07-05 | 2022-05-11 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| MX2022000263A (es) * | 2019-07-05 | 2022-02-03 | The Francis Crick Institute Ltd | Nuevos antigenos y metodos contra el cancer. |
| EP4136096A1 (en) * | 2020-04-17 | 2023-02-22 | The Francis Crick Institute Limited | Antigen pool |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9907691B1 (pt) * | 1998-02-05 | 2011-05-31 | derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. | |
| TR200100916T2 (cg-RX-API-DMAC7.html) * | 1998-07-14 | 2002-06-21 | Corixa@@Corporation | |
| US6770456B1 (en) | 1998-07-29 | 2004-08-03 | Ludwig Institute For Cancer Research | Endogenous retrovirus tumor associated nucleic acids and antigens |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1586330A1 (en) * | 2004-04-16 | 2005-10-19 | Georg-August-Universität Göttingen | Vaccination against malignant melanoma |
| EP2402447A1 (en) | 2005-03-30 | 2012-01-04 | Viroxis | Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment |
| AT502292B1 (de) | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| WO2007109583A2 (en) | 2006-03-17 | 2007-09-27 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| CN101638440B (zh) * | 2008-07-29 | 2011-10-26 | 中国人民解放军军事医学科学院基础医学研究所 | 一种可诱发机体抗肿瘤免疫的异种抗原-Fc融合蛋白及其应用 |
| CN119978090A (zh) * | 2018-10-19 | 2025-05-13 | 弗朗西斯·克里克研究所有限公司 | 新的癌抗原和方法 |
| WO2020260897A1 (en) * | 2019-06-28 | 2020-12-30 | The Francis Crick Institute Limited | Novel cancer antigens and methods |
| MX2022000263A (es) * | 2019-07-05 | 2022-02-03 | The Francis Crick Institute Ltd | Nuevos antigenos y metodos contra el cancer. |
-
2021
- 2021-04-19 EP EP21723936.7A patent/EP4136097A1/en active Pending
- 2021-04-19 CN CN202180043464.9A patent/CN116057067A/zh active Pending
- 2021-04-19 WO PCT/US2021/028029 patent/WO2021212123A1/en not_active Ceased
- 2021-04-19 JP JP2022562788A patent/JP2023522198A/ja active Pending
- 2021-04-19 CA CA3179694A patent/CA3179694A1/en active Pending
-
2022
- 2022-10-14 US US18/046,675 patent/US20230167163A1/en active Pending
-
2026
- 2026-01-21 JP JP2026008257A patent/JP2026086469A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023162283A5 (cg-RX-API-DMAC7.html) | ||
| ES2983085T3 (es) | Fusión que comprende un péptido de penetración celular, un multiepítopo y un agonista peptídico de TLR para el tratamiento de cáncer | |
| US10239916B2 (en) | Controlled modulation of amino acid side chain length of peptide antigens | |
| JP2023513720A5 (cg-RX-API-DMAC7.html) | ||
| ES2398492T3 (es) | Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1 | |
| JP2018510215A5 (cg-RX-API-DMAC7.html) | ||
| US20250312428A1 (en) | Heterologous Prime Boost Vaccine | |
| JP2023542297A5 (cg-RX-API-DMAC7.html) | ||
| JPS63500591A (ja) | プラスモディウム ビバックス スポロゾイド外被タンパク質に相当する免疫原性ペプチド抗原 | |
| JP7686302B2 (ja) | 融合遺伝子、組換え新型コロナウイルス高効率免疫dnaワクチン、それらの構築方法及び使用 | |
| CN104755619A (zh) | 用于预防猪水肿病的疫苗 | |
| Lee et al. | Attachment of flagellin enhances the immunostimulatory activity of a hemagglutinin-ferritin nano-cage | |
| EP2442825B1 (en) | Method for the purification of protein complexes | |
| CA2932211C (en) | Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof | |
| JP2022501046A (ja) | アルギナーゼ1ポリペプチド | |
| JP2023522193A5 (cg-RX-API-DMAC7.html) | ||
| CN1404527A (zh) | Tlp肽以及编码它们的dna序列 | |
| Cano | The multi-epitope polypeptide approach in HIV-1 vaccine development | |
| US11744901B2 (en) | Phage conjugates and uses thereof | |
| CN113185586B (zh) | SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用 | |
| US20060204514A1 (en) | Expression of hydrophobic proteins | |
| CN117177766A (zh) | 疫苗平台 | |
| RU2781294C1 (ru) | Конъюгат белка рецепторсвязывающего домена (RBD) поверхностного гликопротеина S вируса SARS-CoV-2 с полимером полиглюкин-спермидин (PGS) и вакцинный комплекс против коронавирусной инфекции COVID-19 на основе указанного конъюгата и плазмидной ДНК pVAX-RBD | |
| CA3152796A1 (en) | Methods for inducing an immune response against neoantigens | |
| Nimal et al. | Fusion of antigen to Fas-ligand in a DNA vaccine enhances immunogenicity |